Acceleron Pharma(NASDAQ:XLRN) stock News

XLRN Latest News, Press Relases and Analysis

All

Press Releases

3 years ago - By: InvestorPlace - Mentions: AAPL HD MRK OXY ...

3 Dow Stocks to Take Seriously in 2023

4 years ago - By: Avoro Capital Advisors

Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer

4 years ago - By: InvestorPlace - Mentions: PFE MRK BNTX ABBV

Merck Is a Dividend Play Ready to Get Back in Gear

4 years ago - By: The Motley Fool - Mentions: MRK

Is Merck's Planned Acquisition of Acceleron in Trouble?

4 years ago - By: Avoro Capital Advisors

Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer

4 years ago - By: Benzinga - Mentions: INO ACIU JNJ AGTC ...

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data

4 years ago - By: Zacks Investment Research

Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates

4 years ago - By: Acceleron Pharma Inc.

Acceleron Reports Third Quarter 2021 Financial Results

4 years ago - By: Bloomberg - Mentions: MRK

Farallon Capital Opposes Terms of Merck’s Acceleron Takeover

4 years ago - By: Benzinga - Mentions: MRK

Merck Pushes Acceleron Buyout By Refiling For Antitrust Review

4 years ago - By: Zacks Investment Research

Earnings Preview: Acceleron Pharma (XLRN) Q3 Earnings Expected to Decline

4 years ago - By: Halper Sadeh LLP - Mentions: CXP HRC DSPG

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CXP, XLRN, HRC, DSPG; Shareholders are Encouraged to Contact the Firm

4 years ago - By: Zacks Investment Research - Mentions: AZN MRK VRTX

Merck (MRK) Beats on Q3 Earnings & Sales, Ups 2021 View

4 years ago - By: Avoro Capital Advisors

Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders

4 years ago - By: Acceleron Pharma Inc.

Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales

4 years ago - By: Zacks Investment Research - Mentions: AZN PFE MRK

Merck (MRK) to Report Q3 Earnings: What's in the Cards?

4 years ago - By: Halper Sadeh LLP - Mentions: AZPN HRC KOR

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates AZPN, HRC, KOR, XLRN; Shareholders are Encouraged to Contact the Firm

4 years ago - By: Halper Sadeh LLP - Mentions: UMPQ ADMS AZPN

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UMPQ, XLRN, ADMS, AZPN; Shareholders are Encouraged to Contact the Firm

4 years ago - By: Bloomberg - Mentions: BMY MRK

Bristol-Myers Plans to Exit Acceleron Stake With Merck Deal

4 years ago - By: Bragar Eagel & Squire, P.C.

ACCELERON PHARMA ALERT: Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender Offer for XLRN Shares

4 years ago - By: Halper Sadeh LLP - Mentions: COLB AZPN

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates COLB, AZPN, XLRN; Shareholders are Encouraged to Contact the Firm

4 years ago - By: Bloomberg - Mentions: BMY MRK

Bristol-Myers Is Said to Have Weighed Offer for Acceleron

4 years ago - By: Halper Sadeh LLP - Mentions: ECHO EBMT KRA

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XLRN, ECHO, KRA, EBMT; Shareholders are Encouraged to Contact the Firm

4 years ago - By: The Motley Fool - Mentions: MRK

Acceleron Pharma (XLRN) Stock News

XLRN Latest News, Press Relases and Analysis

3 Dow Stocks to Take Seriously in 2023

Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer

Merck Is a Dividend Play Ready to Get Back in Gear

Is Merck's Planned Acquisition of Acceleron in Trouble?

Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data

Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates

Acceleron Reports Third Quarter 2021 Financial Results

Farallon Capital Opposes Terms of Merck’s Acceleron Takeover

Merck Pushes Acceleron Buyout By Refiling For Antitrust Review

Earnings Preview: Acceleron Pharma (XLRN) Q3 Earnings Expected to Decline

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CXP, XLRN, HRC, DSPG; Shareholders are Encouraged to Contact the Firm

Merck (MRK) Beats on Q3 Earnings & Sales, Ups 2021 View

Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders

Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales

Merck (MRK) to Report Q3 Earnings: What's in the Cards?

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates AZPN, HRC, KOR, XLRN; Shareholders are Encouraged to Contact the Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UMPQ, XLRN, ADMS, AZPN; Shareholders are Encouraged to Contact the Firm

Bristol-Myers Plans to Exit Acceleron Stake With Merck Deal

ACCELERON PHARMA ALERT: Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender Offer for XLRN Shares

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates COLB, AZPN, XLRN; Shareholders are Encouraged to Contact the Firm

Bristol-Myers Is Said to Have Weighed Offer for Acceleron

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XLRN, ECHO, KRA, EBMT; Shareholders are Encouraged to Contact the Firm

Is an Acquisition of Acceleron a Smart Move for Merck?